SeekingAlpha•2026-04-16
Q1 2026 In Review - March Dividend Income ReportLMAT — LeMaitre Vascular Inc
NASDAQ · Health Care · Health Care
$111.90+35.19%Market cap2.47B
- Latest Close
- $111.9
- 30-Day Move
- +35.2%
- Market Cap
- $2.5B
- Shares Outstanding
- 22,780,000
- P/E Ratio
- 42.8
- P/B Ratio
- 4.68
Analyst consensus: Buy · 16 analysts
NASDAQ:LMATHealth Care / Health CareDelayed public snapshot
LeMaitre Vascular Inc
A read-only Alphactor snapshot forLeMaitre Vascular Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$111.9
30-Day Move
+35.2%
Market Cap
$2.5B
Shares Outstanding
22,780,000
P/E Ratio
42.8
P/B Ratio
4.68
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$111.90
+35.2%last 90 delayed daily bars
Market cap$2.5B
90D High
$118.01
90D Low
$79.39
Avg Volume
204,656
What stands out
Gross margin is running at 71.5%, which gives a quick read on operating quality before you open the full model.
Net margin is 23.1%, useful for comparing LMAT against peers in Health Care.
LMAT is up 35.2% over the last 30 trading days shown on this page.
Latest operating income is $19M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$46.29
Rule of 40
43.4%
Dark Pool Short %
75.6%
Fundamentals snapshot
Latest Close
$111.9
30-Day Move
+35.2%
Market Cap
$2.5B
Shares Outstanding
22,780,000
P/E Ratio
42.8
P/B Ratio
4.68
ROE
14.7%
ROA
9.4%
Gross Margin
71.5%
Operating Margin
27.2%
Net Margin
23.1%
Debt / Equity
0.43
Current Ratio
12.89
Dividend Yield
93.8%
Latest Revenue
$64M
Financial statement snapshot
Revenue
$64M
Gross Profit
$46M
Operating Income
$19M
Net Income
$16M
Gross Margin
7153.0%
Net Margin
2313.0%
Current Ratio
12.89
Debt / Equity
0.43
Valuation snapshot
Fair Value
$46.29
Upside / Downside
-58.6%
Signal
Overvalued
Implied Growth
13.8%
DCF
$76.57
EPV
$14.43
EV/Rev
$47.88
Growth Assumption
15.6%
Discount Rate
9.0%
Terminal Growth
2.0%
Base FCF
$74M
Valuation spread
Current Price
$111.90
Composite Fair Value
$46.29
DCF
$76.57
EPV
$14.43
EV/Rev
$47.88
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Moderate growth priced in
Quality snapshot
Altman Z
8.70
Safe
Piotroski
8
Strong (7-9)
Cash Conversion
1.41x
Rule of 40
43.4%
Strong
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $162M | $30M | $21M | $22M |
| 2023-12-31 | $193M | $37M | $30M | $29M |
| 2024-12-31 | $220M | $52M | $44M | $37M |
| 2025-12-31 | $250M | $68M | $58M | $74M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$0
Sell Value
$8M
Buys
0
Sells
5
Buy Value
$0
Sell Value
$8M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-26 | SHADAN MARTHA | A | 1 | $0.00 |
| 2026-03-26 | SHADAN MARTHA | A | 1 | $0.00 |
| 2026-03-26 | SHADAN MARTHA | A | 1 | $0.00 |
| 2026-03-26 | SHADAN MARTHA | A | 0 | $0.00 |
| 2026-03-26 | SHADAN MARTHA | A | 0 | $0.00 |
| 2026-03-26 | Roberts David B | A | 4 | $0.00 |
| 2026-03-26 | Roberts David B | A | 0 | $0.00 |
| 2026-03-26 | Roberts David B | A | 0 | $0.00 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 1,267,684 | 0.06% | 2026-02-28 |
| Conestoga Funds-Conestoga Small Cap Fund | 984,321 | 0.04% | 2025-12-31 |
| First TRT Exch-Trd Fd. VI-First TRT SMID Cap Rising Dividend Achievers | 923,436 | 0.04% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 647,996 | 0.03% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 500,372 | 0.02% | 2026-02-28 |
| Professionally Managed Portfolios-Congress Small Cap Growth Fund | 445,000 | 0.02% | 2026-03-31 |
| Nationwide Mutual Funds-Nationwide Geneva Small Cap Growth Fund | 249,927 | 0.01% | 2026-01-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 224,328 | 0.01% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
BlackRock
Filed 2024-08-13
$286M
--
Vanguard Group
Filed 2025-11-07
$140M
-0.1%
Geode Capital Management
Filed 2026-02-09
$51M
+20.1%
Goldman Sachs
Filed 2026-02-10
$32M
+144.4%
Northern Trust
Filed 2025-11-14
$29M
-1.9%
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
4
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
16
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.